The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia - PubMed (original) (raw)
Review
The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
Jan Cools et al. Curr Opin Hematol. 2004 Jan.
Abstract
Purpose of review: The idiopathic hypereosinophilic syndrome is a rare hematologic disorder characterized by sustained unexplained eosinophilia with associated end-organ damage and by a striking male predominance. The first insights into the molecular etiology of this heterogeneous disease were obtained from a "bedside-to-bench" approach. Successful empiric treatment of patients with the hypereosinophilic syndrome with the selective tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis) ultimately led to the discovery of the FIP1L1-PDGFRalpha fusion kinase in about half of the hypereosinophilic syndrome cases.
Recent findings: The FIP1L1-PDGFRA fusion gene is generated by a cryptic interstitial chromosomal deletion, del(4)(q12q12), which indicates that these cases are clonal hematopoietic malignancies and should be reclassified as chronic eosinophilic leukemias based on current World Health Organization recommendations. In addition, the FIP1L1-PDGFRA fusion gene was also identified in cases with systemic mast cell disease. In vitro and in vivo studies confirmed that FIP1L1-PDGFRalpha is a therapeutic target of imatinib, forming a rational basis for the treatment of FIP1L1-PDGFRA positive chronic eosinophilic leukemia and mastocytosis with imatinib. Similar to BCR-ABL-positive leukemias, resistance to imatinib due to point mutations in the PDGFRalpha kinase domain may develop. We have explored strategies to circumvent resistance to imatinib using alternative tyrosine kinase inhibitors such as PKC412.
Summary: The discovery of the FIP1L1-PDGFRA fusion gene in the hypereosinophilic syndrome is an example of the power of clinical translational research and identifies interstitial chromosomal deletion as a novel mechanism to generate oncogenic tyrosine kinase fusion genes.
Similar articles
- The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. Gotlib J, et al. Blood. 2004 Apr 15;103(8):2879-91. doi: 10.1182/blood-2003-06-1824. Epub 2003 Nov 20. Blood. 2004. PMID: 15070659 Review. - CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A. Pardanani A, et al. Blood. 2003 Nov 1;102(9):3093-6. doi: 10.1182/blood-2003-05-1627. Epub 2003 Jul 3. Blood. 2003. PMID: 12842979 - A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU. Salemi S, et al. Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7. Allergy. 2009. PMID: 19210352 - FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ. Wang LN, et al. Chin Med J (Engl). 2008 May 20;121(10):867-73. Chin Med J (Engl). 2008. PMID: 18706197 - FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G, Cools J, Stover EH, Wlodarska I, Marynen P. Gilliland G, et al. Hematol J. 2004;5 Suppl 3:S133-7. doi: 10.1038/sj.thj.6200439. Hematol J. 2004. PMID: 15190295 Review. No abstract available.
Cited by
- A pan-cancer analysis of the core pre-mRNA 3' end processing factors, and their association with prognosis, tumor microenvironment, and potential targets.
Li X, Che Y, Wang X, Zhu Y. Li X, et al. Sci Rep. 2024 Jul 29;14(1):17428. doi: 10.1038/s41598-024-57402-6. Sci Rep. 2024. PMID: 39075070 Free PMC article. - Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.
Nourse J, Spada S, Danckwardt S. Nourse J, et al. Biomolecules. 2020 Jun 17;10(6):915. doi: 10.3390/biom10060915. Biomolecules. 2020. PMID: 32560344 Free PMC article. Review. - Targeting cleavage and polyadenylation specific factor 1 via shRNA inhibits cell proliferation in human ovarian cancer.
Zhang B, Liu Y, Liu D, Yang L. Zhang B, et al. J Biosci. 2017 Sep;42(3):417-425. doi: 10.1007/s12038-017-9701-x. J Biosci. 2017. PMID: 29358555 - Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib.
Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Fraticelli P, et al. World J Clin Cases. 2016 Oct 16;4(10):328-332. doi: 10.12998/wjcc.v4.i10.328. World J Clin Cases. 2016. PMID: 27803915 Free PMC article. - The epigenetic signature of systemic insulin resistance in obese women.
Arner P, Sahlqvist AS, Sinha I, Xu H, Yao X, Waterworth D, Rajpal D, Loomis AK, Freudenberg JM, Johnson T, Thorell A, Näslund E, Ryden M, Dahlman I. Arner P, et al. Diabetologia. 2016 Nov;59(11):2393-2405. doi: 10.1007/s00125-016-4074-5. Epub 2016 Aug 18. Diabetologia. 2016. PMID: 27535281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous